R&D News | pharmaphorum

News

PEAR raises $50m to develop digital therapeutics business

PEAR Therapeutics has raised $50m in a new financing round to fund development of its prescription digital therapeutics business.

News

Janssen's depression drug shows promise in phase 2

Ketamine may be best known as an anaesthetic illegally used as a party drug, but Janssen has shown that it could also be reformulated and used as a treatment for depression.

News

NICE to reassess Pfizer blood cancer drug

Company successfully appealed against rejection last summer

PEAR raises $50m to develop digital therapeutics business

Janssen's depression drug shows promise in phase 2

NICE to reassess Pfizer blood cancer drug

BMS shakes up R&D under CMO Cristian Massacesi

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks